Status:
COMPLETED
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
Lead Sponsor:
Duke University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them ...
Detailed Description
OBJECTIVES: Primary * Determine the pharmacogenomics of adjuvant chemotherapy comprising doxorubicin and cyclophosphamide and/or paclitaxel in women with nonmetastatic invasive breast cancer. * Dete...
Eligibility Criteria
Inclusion
- Eligibility Criteria
- Histologically confirmed invasive breast cancer
- node negative stage \> T1c or T1b with poor prognostic features (high grade, Her2/neu FISH positive, ER negative) or stage 2 (T2, N0) or
- enrolled on CALGB 40101, CALGB 49909, or the National Cancer Institute of Canada study MA-21 or
- any node positive patient or locally advanced undergoing neoadjuvant chemotherapy with either AC or paclitaxel
- Age greater than or equal to 18 years.
- \>/=2 weeks from major surgery (wide excision / lumpectomy / mastectomy)
- No evidence of systemic metastasis
- Undergoing adjuvant treatment with standard dose AC or AC followed by weekly Paclitaxel at 80mg/m2
- Adequate bone marrow, hepatic and renal functions (absolute neutrophil count \>1,500/ μl, platelet count \> 100,000/ μl, serum creatinine \<2.0 mg/dl, total Bilirubin \<2.0 x the upper limit of normal (ULN)
- Ability to answer and understand study surveillance questionnaires
- No concurrent drug therapy (within 2 weeks) with agents that are known inducers or inhibitors of Cytochrome P450 (CYP450).
- Exclusion Criteria
- Other anticancer cytotoxic or endocrine therapy, immunotherapy, or biologic response modifiers,Study Drugs or other concomitant medications known to cause myelosuppression especially neutropenia and neuropathy
- Eastern Cooperative Oncology Group Performance Status(ECOG) functional status \> 2.
- Serious co-morbidities including poorly controlled diabetes mellitus, ischaemic heart disease,uncontrolled hypertension or active infection.
- Pregnancy
- Use of growth factor during cycle 1 of chemotherapy (AC) under pharmacokinetic evaluation
- Grade \>/=2 peripheral neuropathy symptoms based on National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE) Scale. Exception: a chronic neurologic disorder will be reviewed on a case by case basis by the study PI.
- Prior treatment with weekly paclitaxelDISEASE CHARACTERISTICS:
- Histologically confirmed invasive breast cancer, meeting 1 of the following criteria:
- Node negative disease AND meets 1 of the following stage criteria:
- Primary tumor \> T1c
- Primary tumor \> T1b AND poor prognostic features, defined as the following:
- High-grade disease
- Human Epidermal Growth Factor Receptor 2 (HER2)/neu-positive disease by fluorescence in situ hybridization
- Estrogen receptor-negative disease
- Stage II disease (T2, N0)
- Node positive nonmetastatic disease
- Locally advanced disease AND receiving neoadjuvant chemotherapy comprising doxorubicin and cyclophosphamide OR paclitaxel
- Enrolled in clinical trial CALGB-40101
- No evidence of systemic metastasis
- Hormone receptor status:
- Not specified
Exclusion
Key Trial Info
Start Date :
October 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT00131963
Start Date
October 1 2003
End Date
October 1 2014
Last Update
July 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Cancer Institute
Durham, North Carolina, United States, 27710